Stem Cell Therapeutics Corp has been advised by the Data Safety Monitoring Board (DSMB) that its third and final regularly scheduled safety analysis has been completed and the DSMB has recommended for the phase-IIb acute ischemic stroke trial to continue as per protocol.

Dr Alan Moore, president and CEO, said, "Since the initiation of the modified REGENESIS phase-IIb acute ischemic stroke study, 96 patients have been enrolled in the study. We continue to anticipate that patient enrolment for the phase-IIb stroke trial will be complete by the end of Q1 2010 and for top-line data to be available after the 90-day patient assessment review period is complete, approximately by the end of Q2 2010."

The DSMB is a group of independent clinical experts that review the ongoing conduct of a clinical trial to ensure continuing patient safety.

Stem Cell Therapeutics Corp. is a public biotechnology company focused on the development and commercialization of drug-based therapies to treat central nervous system diseases.